Silverback Therapeutics Competitors

Silverback Therapeutics (NASDAQ:SBTX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Silverback Therapeutics and Sana Biotechnology's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Silverback Therapeutics and Sana Biotechnology, as reported by MarketBeat.

Silverback Therapeutics currently has a consensus target price of $46.25, indicating a potential downside of 9.62%. Sana Biotechnology has a consensus target price of $40.00, indicating a potential upside of 63.73%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Silverback Therapeutics.

Earnings and Valuation

This table compares Silverback Therapeutics and Sana Biotechnology's gross revenue, earnings per share (EPS) and valuation.

Summary

Silverback Therapeutics beats Sana Biotechnology on 2 of the 3 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Silverback Therapeutics and Abcam's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Silverback Therapeutics and Abcam, as reported by MarketBeat.

Silverback Therapeutics currently has a consensus target price of $46.25, indicating a potential downside of 9.62%. Abcam has a consensus target price of $22.3333, indicating a potential upside of 0.78%. Given Abcam's higher probable upside, analysts clearly believe Abcam is more favorable than Silverback Therapeutics.

Earnings and Valuation

This table compares Silverback Therapeutics and Abcam's gross revenue, earnings per share (EPS) and valuation.

Summary

Silverback Therapeutics beats Abcam on 2 of the 3 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and Seer (NASDAQ:SEER) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Silverback Therapeutics and Seer's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Silverback Therapeutics and Seer, as reported by MarketBeat.

Silverback Therapeutics currently has a consensus target price of $46.25, indicating a potential downside of 9.62%. Seer has a consensus target price of $69.6667, indicating a potential upside of 39.25%. Given Seer's higher probable upside, analysts clearly believe Seer is more favorable than Silverback Therapeutics.

Earnings and Valuation

This table compares Silverback Therapeutics and Seer's gross revenue, earnings per share (EPS) and valuation.

Summary

Silverback Therapeutics beats Seer on 2 of the 3 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and Cullinan Management (NASDAQ:CGEM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.

Earnings and Valuation

This table compares Silverback Therapeutics and Cullinan Management's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Silverback Therapeutics and Cullinan Management, as reported by MarketBeat.

Silverback Therapeutics currently has a consensus target price of $46.25, indicating a potential downside of 9.62%. Cullinan Management has a consensus target price of $48.00, indicating a potential downside of 8.57%. Given Cullinan Management's higher probable upside, analysts clearly believe Cullinan Management is more favorable than Silverback Therapeutics.

Profitability

This table compares Silverback Therapeutics and Cullinan Management's net margins, return on equity and return on assets.

Summary

Silverback Therapeutics beats Cullinan Management on 2 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Earnings & Valuation

This table compares BioAtla and Silverback Therapeutics' gross revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for BioAtla and Silverback Therapeutics, as reported by MarketBeat.com.

BioAtla currently has a consensus target price of $48.00, indicating a potential downside of 5.88%. Silverback Therapeutics has a consensus target price of $46.25, indicating a potential downside of 9.62%. Given BioAtla's higher probable upside, research analysts plainly believe BioAtla is more favorable than Silverback Therapeutics.

Profitability

This table compares BioAtla and Silverback Therapeutics' net margins, return on equity and return on assets.

Summary

BioAtla beats Silverback Therapeutics on 1 of the 1 factors compared between the two stocks.

Gracell Biotechnologies (NASDAQ:GRCL) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Gracell Biotechnologies and Silverback Therapeutics, as reported by MarketBeat.com.

Gracell Biotechnologies currently has a consensus target price of $34.50, indicating a potential upside of 46.19%. Silverback Therapeutics has a consensus target price of $46.25, indicating a potential downside of 9.62%. Given Gracell Biotechnologies' higher probable upside, research analysts plainly believe Gracell Biotechnologies is more favorable than Silverback Therapeutics.

Earnings & Valuation

This table compares Gracell Biotechnologies and Silverback Therapeutics' gross revenue, earnings per share and valuation.

Profitability

This table compares Gracell Biotechnologies and Silverback Therapeutics' net margins, return on equity and return on assets.

Summary

Gracell Biotechnologies beats Silverback Therapeutics on 1 of the 1 factors compared between the two stocks.